Citation:Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al 2011

Citation

Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011 Jul;100(1):76-85 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21757247.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al 2011	What is the best practice radiotherapy approach in patients with stage I inoperable NSCLC?	Professor David Ball MB BS, MD, FRANCZR	completed
Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al 2011 2	What is the best practice radiotherapy approach in patients with stage II inoperable NSCLC?	Professor David Ball MB BS, MD, FRANCZR	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the best practice radiotherapy approach in patients with stage I inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the best practice radiotherapy approach in patients with stage II inoperable NSCLC?|]] (compare critical appraisals)

Cited by

1. What is the best practice radiotherapy approach in patients with stage I inoperable NSCLC?
2. What is the best practice radiotherapy approach in patients with stage II inoperable NSCLC?
3. What is the optimal radiation dose and fractionation schedule for good performance status patients with inoperable stage III NSCLC undergoing curative therapy?